March 28, 2023
Tighter fiscal “conditions,” share pricing ranges, uncertain capital markets access, faltering runways are some of the effects of heightened financial market volatility with uncertain sentiment
News: Voyager Therapeutics (VYGR) presented new data from its anti-tau antibody program for Alzheimer’s disease (AD) and from its GBA1 gene therapy program for Parkinson’s disease (PD) and other GBA1-mediated diseases at the AD/PD™ Conference in Gothenburg, Sweden.
Pre-open Indications: 3 Negative Indications and 3 Sell into Strength
A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
The 8:00 a.m. edition
March 23, 2023
The cell and gene therapy sector fluctuates in revenues, collaboration, regulatory submissions and expenses, but the changes may alarm investors who prefer to see expectation and consensus stability and share pricing growth.
Stock pricing rises or falls before and after an earnings announcement, depending on whether the earnings meet or fall short of expectations.
To date … 28 of 35 (adding AVRO and SLDB)
March 27, 2023
Sentiment has hop-scotched forward while conviction is still in doubt
News: Agenus (AGEN +$0.07) announced results from a cohort of 24 evaluable patients in an expansion of the P1b study of botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) in patients with recurrent platinum resistant/refractory ovarian cancer. These findings, presented in an oral plenary session at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, showed a 33% overall response rate (ORR).
Pre-open Indications: 5 Hits and 2 Miss
I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about - truth!
Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
March 23, 2023
The cell and gene therapy sector fluctuates in revenues, collaboration, regulatory submissions and expenses, but the changes may alarm investors who prefer to see expectation and consensus stability and share pricing growth. Stock pricing rises or falls before and after an earnings announcement, depending on whether the earnings meet or fall short of expectations. To date … 28 of 35 (adding AVRO and SLDB)
March 17, 2023
“Protection for reorganization” … ?? Breaking news SVB Financial Group on Friday it filed for a court-supervised reorganization under Chapter 11 bankruptcy protection to seek buyers for its assets, days after its former unit Silicon Valley Bank was taken over by U.S. regulators. <CNBC>
March 13, 2023
SVB clients got a painful lesson: SVB have lulled depositors into a false sense of security – that’s well over or soon to be. Thanks to the FDI, Treasury, and Federal Reserve – if not a biotech, cell and gene therapy companies would NOT be feeding their employees.
© 2023 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
